1. Introduction {#sec1}
===============

The female immune system faces a delicate balancing act during pregnancy. On one hand, it must develop tolerance to paternal antigens to avoid a lethal immunologic attack against the fetus. On the other hand, it must preserve the ability to fight infections from a multitude of commensal and environmental pathogens. Disruption of this balance can have devastating consequences, including preterm labor and death of the fetus and/or mother. The normal maternal immune response to pregnancy is increasingly recognized as a dynamic process, with changes in the maternal pro/anti-inflammatory profile occurring at different stages of gestation \[[@B1]--[@B3]\]. Despite this recognition, a complete, longitudinal immunologic profile of normal pregnancy has not been performed. Such analyses are critical for understanding the response to specific infectious and immunologic diseases that show disproportionately negative outcomes during pregnancy, such as influenza \[[@B4]\] and ulcerative colitis \[[@B5]\].

One approach to such immune profiling is through the use of multiplex cytokine arrays, allowing for simultaneous quantification of many proteins with a very small amount of plasma or serum. Others have used multiplex arrays to study the maternal cytokine milieu, but the studies have been predominantly limited time point cross-sectional \[[@B6]--[@B8]\] or case-control \[[@B9]--[@B11]\] in design. The results of some longitudinal studies have been published in recent years, although results have been based on relatively few time points (5 or fewer) \[[@B1]--[@B3]\]. In this study, we applied the multiplex array approach to evaluate the changes in 42 cytokines in rich detail during pregnancy. The samples are from a cohort of 16 pregnant women, with each subject sampled a median of 18 times. Because this represents a significant increase in the number of tests per subject compared to previous studies, we also describe a strategy addressing within-subject correlation with repeated measurements using unconditional growth modeling. With this approach, we have been able to detail the typical longitudinal variation of serum cytokines throughout pregnancy in this cohort of women.

2. Materials and Methods {#sec2}
========================

2.1. Participants {#sec2.1}
-----------------

Archived longitudinal serum samples from 16 primigravid women were tested in this study. Each participant had a serum sample collected and cryopreserved biweekly from study enrollment during the first trimester (average of 9.7 weeks\' gestation for first samples) until 34 weeks\' gestation, then weekly from 34 weeks until delivery. As a result of this repeated sampling, a median of 18 samples per participant were obtained longitudinally throughout pregnancy. A total of 312 longitudinal pregnancy samples were tested. Samples were collected under a protocol approved by the Mayo Clinic Institutional Review Board (IRB) that accrued participants from 1987 to 1988. IRB approval was obtained for analysis of these archived samples and clinical data. Information regarding date of the blood draw, date of delivery, outcome of the delivery, and any major complications that the woman experienced during pregnancy (hypertensive disorders, preterm labor, and infections) was available and helped identify appropriate participants to include. Only women who carried their pregnancies to term and experienced no pregnancy complications were included in this study. We only used samples from subjects who had specimens obtained throughout the entire course of pregnancy and whose complete, longitudinally collected specimens appeared intact and nondesiccated. Most cytokines are stable in storage at −80 degrees C for up to 2 years \[[@B12]\], but stability beyond that time is not well known. Therefore, before proceeding with studies on the samples of interest, we first tested protein levels of a small number of individually stored serum aliquots from other subjects archived on this protocol. Since we found detectable levels of cytokines in the pregnant serum samples that were within range of control samples, we proceeded with the entire study involving a cohort of 16 healthy, primigravid women who completed a term pregnancy without any significant complications. Samples were assayed when freshly thawed to avoid freeze-thaw cycles, which are known to degrade cytokines \[[@B12]\].

Contemporary plasma samples from 11 nonpregnant control subjects were collected under a separate IRB-approved protocol for collection of biospecimens from healthy individuals within the same health system in 2010 and similarly assessed on the same 96-well plates for comparison and as a quality control measure. For contemporary nonpregnant control samples, peripheral venous blood was drawn into heparinized Vacutainer tubes that were processed and separated into plasma and peripheral blood mononuclear cells (PBMCs) following gradient centrifugation using Ficoll-Paque (GE Healthcare, Uppsala, Sweden). Plasma was collected and immediately frozen at −80°C in 1 mL aliquots until use.

2.2. Multiplex Serum and Plasma Cytokine Concentration Determination {#sec2.2}
--------------------------------------------------------------------

Protein levels for 42 cytokines, chemokines, and growth factors ([Table 1](#tab1){ref-type="table"}) were measured using the MILLIPLEX MAP Human Cytokine/Chemokine Kit (Millipore, Billerica, MA, USA) per manufacturer\'s instructions. To minimize the potential for interassay variability, each subject had all of their longitudinal specimens analyzed on the same plate. Plasma/serum samples were not diluted prior to incubation with fluorescently dyed microspheres. Protein concentrations were determined using a linear regression standard curve from each plate generated using the high PMT concentrations with sensitivity from 3.2 to 2,000 pg/mL. All samples were tested in duplicate with the mean value of the measurements used for statistical analyses.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Comparison of baseline (first trimester) and end of pregnancy levels of cytokines/growth factors was carried out between the 16 primigravid subjects and the 11 nonpregnant control subjects using the Kruskal-Wallis tests. There were extremes of values that fell outside of the limits of the multiplex array. For cytokines below the limit of detection (LD), we assigned a value that was half the lowest detectable value for the assay as previously described \[[@B13]\]. Analytes above the detectable range were assigned a threshold concentration \[[@B14]\]. To obtain a visual representation of overall patterns in the highly dimensional raw data, we performed unsupervised hierarchical clustering according to Ward\'s method \[[@B15]\]. As an additional multivariate technique to identify patterns within the data, principle components analysis (PCA) was also completed on the raw values obtained from the multiplex array.

2.4. Data Normalization {#sec2.4}
-----------------------

To assess the within-subject correlation, we determined change of cytokines and growth factors from a baseline time point---the values obtained from the participants\' first blood draw in the first trimester---by taking the log of 1 plus fold change from the baseline value: log⁡(1 + *x*), where *x* = (cytokine concentration of the sample of interest/cytokine concentration of the baseline sample) to analyze trends over time.

2.5. Longitudinal Analyses {#sec2.5}
--------------------------

First, we graphically assessed the growth trajectory for the 42 cytokines using smoothing splines. These plots were used to help visually determine within-subject variation over time. We then fit unconditional mean models (UMM) for the 42 cytokines in order to estimate the variance components: the within-subject variance (*σ* ~*ε*~ ^2^) and the between-subject variance (*σ* ~0~ ^2^). Estimating the two variance components helps to determine whether there is sufficient variation to warrant further analysis and enabled computations of the intraclass correlation coefficient, *ρ*, which describes the proportion of the total outcome variation that lies between subjects.

Next, we fit unconditional growth models (UGM), which allowed random slope but not random intercept because the starting value of all patients was the same (baseline value = 0.3) due to normalization to each individual\'s baseline value. As both gestational age in weeks and trimester can be used as the time covariate for growth curve models, and as the trimester can be treated as either a continuous or a categorical variable (depending on whether we assume linear relationship between trimester and outcome variables), six different models were fitted for each cytokines as follows: (1) model with only the gestational age in weeks as the time covariate, (2) model with only the trimester (continuous) as the time covariate, (3) model with only the trimester (categorical) as the time covariate, where the variance-covariance pattern was assumed to be autoregressive, (4) model with both gestational age in weeks and continuous trimester as covariates, allowing random slope for gestational time in weeks, (5) model with both gestational age in weeks and continuous trimester as a covariate, allowing random slope for trimester, and (6) model with both gestational age in weeks and continuous trimester as a covariate, allowing random slopes for both gestational age in weeks and trimester. We then compared the six models and the unconditional mean model for each of the cytokines based on logic and statistical fitness, using Akaike information criteria (AIC) \[[@B16]\]. Because of the exploratory nature of this study, there was no correction for multiple comparisons.

3. Results {#sec3}
==========

3.1. Detection Limits {#sec3.1}
---------------------

The multiplex was designed to assess 42 factors, but the limits of detection were exceeded with three factors, and there were 5 cytokines that fell below the limit of detection in \>50% of the samples. PDGF-AA, PDGF-AB/BB, and RANTES had cytokine levels above detection limits of the assay in 9.9%, 11.2%, and 34.9% of the samples, respectively (Table S1; see Supplementary Material available online at <http://dx.doi.org/10.1155/2015/952571>). IL-2, IL-3, IL-4, IL-13, and TNF*β* had \>50% of the samples below the detection limit (Table S1).

3.2. Comparison between Pregnant and Nonpregnant Samples {#sec3.2}
--------------------------------------------------------

Differences in cytokine profiles between baseline (first trimester) pregnancy samples and nonpregnant control samples could be identified by PCA ([Figure 1](#fig1){ref-type="fig"}). Specifically, we identified significantly higher levels of GRO*α*, TGF*α*, EGF, PDGF-AA, and PDGF-AB/BB and significantly lower levels of sCD40L, IP-10, IL-6, IL-17, IL-13, and MCP-1 in the baseline pregnancy samples ([Table 1](#tab1){ref-type="table"}). When all longitudinal samples were included in a PCA, no difference could otherwise be identified between sample groups. Next, we evaluated whether those differences apparent in early gestation were also present at the end of pregnancy. When comparing the final independent samples obtained at the end of pregnancy to the healthy control samples, the following remained significantly elevated in pregnant women: EGF (330.6 versus 24.8 pg/mL, *P* = 0.0013), GRO*α* (1,153.6 versus 341.6 pg/mL, *P* \< 0.001), sIL-2Ra (17.9 pg/mL versus LLD, *P* = 0.02), and TGF*α* (15.8 versus 1.8 pg/mL, *P* = 0.0006). Meanwhile, only eotaxin was lower in women at the end of pregnancy compared to normal controls (33.4 versus 330.0 pg/mL, *P* \< 0.001).

3.3. Longitudinal Analyses {#sec3.3}
--------------------------

To begin to assess within-subject variation, we clustered the raw data ([Figure 2](#fig2){ref-type="fig"}), where the issue of correlation within subjects becomes visually apparent. Subject-specific "bands" or cytokine fingerprints appear in the cluster map. Empirical growth plots demonstrated that the within-subject variation differs among different women (Figures [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} show a representative example using IL-15, and the remainder of the plots can be viewed in Supplementary Figures). In other words, some women display more variability than others. For example, patient O displays very large variation in the majority of the cytokines tested, whereas patients B, C, F, and G have comparatively steady levels for most cytokines. Also, high variability in one cytokine does not imply high variability in other cytokines for the individual women.

3.4. Unconditional Mean Models {#sec3.4}
------------------------------

High interclass correlation (≥0.7) was observed for sCD40L, RANTES, IL-10, TNF*β*, IL-7, and GM-CSF (Table S2). This means that the majority of the variability in these cytokines is attributed to variance between subjects. The interclass correlations were comparatively low (\<0.3) for IL-3, IL-4, MCP-3, and IP-10, suggesting more variation within subjects for these cytokines.

### 3.4.1. Cytokines with Gestational Weeks (GW) as Final Model {#sec3.4.1}

The final model for MDC ([Table 2](#tab2){ref-type="table"}) was UGM with GW, with a decreasing trajectory. The estimated variance for the random slope is 0.000001632, suggesting that the variability of slope among patients is quite small. On the other hand, the average scatter of an individual\'s outcome around her own trajectory is larger (the estimated variance is 0.000937, *P* \< 0.0001), suggesting that there might be some other important covariates that are not included in the model. However, including gestational age in weeks as a covariate does substantially improve the fit of the model. When comparing the estimated within-subject variance of the UGM with that from the UMM, we found that the linear gestational age in weeks helps to explain 34% of the within-subject variation in MDC. The estimated fixed effect suggests that MDC decreases over time (the estimated slope is −0.00163, with *P* ≤ 0.0001, suggesting that the slope is significantly lesser than 0, Figure S2). Eight other cytokines demonstrated statistical significance, although with increasing trajectories, with UGM and GW as a covariate: IL-1*β*, IL-6, IL-8, IL-12p70, IL-13, IL-15, IP-10, and FLT3-ligand ([Table 2](#tab2){ref-type="table"}).

### 3.4.2. Cytokines with Trimester as Final Model {#sec3.4.2}

Six cytokines showed association with trimester as a linear variable: IL-1ra, IL-3, IL-9, IL-12p40, IFN*α*2, and sCD40L ([Table 3](#tab3){ref-type="table"}). IL-1ra showed the greatest percent explanation by inclusion of linear trimester in the model. When comparing the estimated within-subject variance of the UMM with that from the UGM, we found that the linear trimester helps to explain 27% of the within-subject variation in IL-1ra. Seven other cytokines showed significant associations with trimester as a categorical variable: IL-4, IFN*γ*, G-CSF, TGF-*α*, TNF-*β*, sIL-2ra, and MIP-1*α* ([Table 4](#tab4){ref-type="table"}).

### 3.4.3. No Change over Time {#sec3.4.3}

The final model for both EGF and VEGF was UMM with intercept only, leading to the conclusion that both EGF and VEGF do not change over time. Time-dependent UGM models were identified but did not meet statistical significance for the following cytokines: IL-2, IL-5, PDGF-AA, PDGF-AB, MIP-1*β*, GRO*α*, MCP-1, MCP-3, RANTES, IL-17, IL-7, eotaxin, FGF-2, IL-10, TNF*α*, IL-1ra2, fracktalkine, and GM-CSF. Therefore, approximately 50% of cytokines measured by multiplex array did not show any association with gestational week or trimester.

4. Discussion {#sec4}
=============

Our results suggest that the third trimester of pregnancy is characterized by an increasingly inflammatory (e.g., IL-1*β*, IL-6, IL-12, IL-15, IP-10, and sCD40 ligand) as well as counterregulatory (e.g., IL-1ra and FLT3-ligand) milieu compared to earlier stages of pregnancy. Our superimposed growth curves of IL-15 ([Figure 4](#fig4){ref-type="fig"}) and IL-1*β* (Figure S3), the cytokines with the strongest association with gestational week as a linear covariate, suggest that this change begins at approximately week 20 and peaks just after week 30. This is consistent with other reports of systemic immune activation as well as counterregulation in the latter part of pregnancy \[[@B3], [@B17]--[@B19]\]. Increasing IL-1*β* and IL-15 may predominantly be related to production from placental tissues \[[@B20], [@B21]\] or mononuclear phagocytes \[[@B22], [@B23]\] in late gestation. The precise immunologic mechanisms responsible for this shift cannot be determined by our study, but if the source of these cytokines is predominantly the innate immune system, one potential stimulus to these cytokines\' secretion is cell-free fetal DNA. A recently proposed model links rising circulating levels of fetal DNA to maternal innate immune activation via toll-like receptor- (TLR-) 9 on neutrophils and macrophages, leading to increasing inflammatory cytokine release, that may result in an immune cascade ultimately leading to parturition \[[@B24]\].

A novel finding of this study is the decline in MDC levels throughout pregnancy ([Figure 5](#fig5){ref-type="fig"}). MDC is chemoattractant for immature dendritic cells \[[@B25]\] and type 2-biased T cells \[[@B26]\], and it is possible that decreasing MDC levels may reflect a gradual shift away from a self-amplifying type 2 immune response as pregnancy progresses. Another novel finding of this study is the increasing levels of IL-9 per trimester. IL-9 is cytokine that has been recognized for decades but only recently had its cell of origin identified: the innate lymphoid cell (ILC) \[[@B27]\]. The role of IL-9, which has historically been categorized as a Th2 cytokine prior to the recognition of ILC \[[@B28]\], is currently unknown in normal pregnancy. Because only serum was available for analysis, we cannot confirm the cellular source of the changes observed with this cohort. Nonetheless, increasing transcription levels of several innate immune components, including*CD14*, multiple*TLR* genes, and*IL-1B*, have been observed in peripheral blood leukocytes of women in the third trimester \[[@B19]\], suggesting that the changes in concentrations of the cytokines identified in our study could plausibly be due to changes in peripheral blood cellular composition. Further studies will be necessary to determine whether placental tissues, circulating leukocytes, stromal cells, or other sources also contribute to the changes reflected in our results.

Although these results show statistical significance, it is also noteworthy that the slopes of the variance were all fairly small for each of the analytes and that gestational week did not explain any more than 40% of the variation observed in any of the cytokines. Pregnancy clearly alters the maternal immune milieu, but the changes from baseline in the setting of normal pregnancy are subtle and more variable in some women than in others. What clinical factors contribute to this variation observed between women in the setting of a normal first pregnancy is not entirely known. Blood draws and resulting data were relatively sparse in the first trimester due to women not returning as frequently for study blood draws, even though they were scheduled per protocol, relative to the second and third trimesters. It is also important to note that many analytes were not detectable in samples; therefore, it is possible that a different method besides multiplex array on serum or plasma, for example, ELISA for individual cytokines/growth factors, may be more sensitive to detect change over time.

Previous longitudinal studies of maternal cytokines during pregnancy have shown some concordance with our results. Curry et al. investigated the change of maternal plasma cytokines from early to midgestation in a large cohort (approximately 1,000 patients) and found that IL-12 and IFN*γ* levels increased, while IL-2 and GM-CSF levels decreased as pregnancy progressed \[[@B1]\]. Our results confirmed increasing IL-12 levels, as well as an increase of IFN*γ* in the third trimester compared to the first. However, Kraus et al. published maternal multiplex ELISA results from 50 women tested at each trimester as well as postpartum and showed that IFN*γ* levels decreased throughout gestation \[[@B2]\]. Denney et al. also found that basal levels of IFN*γ* decreased throughout gestation, as did levels of TNF*α*, IL-1*β*, and IL-6 in serum samples of 45 healthy pregnant women collected during each trimester \[[@B3]\]. Another recent study demonstrated decreasing IL-1*β* levels throughout gestation \[[@B29]\]. While our study did not confirm any time-dependent change of TNF*α*, we instead observed increases in IL-1*β* and IL-6 throughout pregnancy, in contrast to these studies. Clearly, individual heterogeneity exists, and our smaller sample size may account for some of these differences with prior studies.

Although not the original focus of this study, we also identified several differences in cytokine/growth factor milieu when comparing pregnant women to healthy controls. Notably, the first trimester of pregnancy was characterized by an increase in several growth factors (GRO*α*, EGF, TGF*α*, and PDGF) and a relative decrease in inflammatory markers (sCD40L, IL-6, IL-17, IP-10, eotaxin, and MCP-1). Eotaxin, a potent chemoattractant for eosinophils during allergic reactions, has been similarly described to be suppressed during pregnancy by Kraus et al. \[[@B2]\]. Overall, the tolerance induction required for successful pregnancy at the level of the fetomaternal interface may also be observed in a relatively tolerogenic, growth factor-rich maternal systemic environment. The difference in sample source when comparing the archived samples from healthy pregnant women (serum) and normal controls (plasma) may contribute to these findings. For example, eotaxin, PDGF, EGF, VEGF, and soluble CD40 ligand have previously been shown to be significantly different in serum postclotting as compared to plasma samples \[[@B30]\]. Because of this potential source of variation in comparing our historical to contemporary samples, our results will require validation with similarly processed samples of the same source. However, EGF levels have been reported to be approximately 65 pg/mL in serum of healthy individuals \[[@B30]\], well below our median 489.4 pg/mL in our samples obtained from pregnant subjects, suggesting that our results may hold true despite differences in sample source. Similarly, serum levels of CD40L have been shown to be 8--30-fold higher in serum as compared to plasma \[[@B30]\], suggesting again that the very low levels identified in the serum of our cohort of pregnant women may indeed be reflective of the pregnancy state.

Our study is unique in that the longitudinal samples were obtained frequently throughout the course of pregnancy. Because of this, our study has the potential to more richly describe individual maternal immune variation over time. However, our study is limited by the relatively small sample size, the lack of pre- or postpartum samples, and potentially the age of the specimens. To address these limitations, we have recently conducted a larger longitudinal study of maternal immune changes during pregnancy, with peripheral blood samples obtained monthly throughout gestation as well as 6 weeks postpartum. Analysis of the clinical and laboratory data from our most recent study is ongoing.

Tolerance at the fetomaternal interface is complex and technically challenging to study in humans longitudinally. As a result, many recent studies have sought to understand how pregnancy changes maternal systemic immunity. The possibility exists of maternal peripheral blood not completely or accurately reflecting the local changes within decidual tissues. An example of such a discrepancy in our study is that of IP-10, which was low in first-trimester pregnancy compared to healthy controls in this cohort. IP-10 is secreted by decidual natural killer cells and is key to trophoblast migration and thus has previously been shown to be elevated during pregnancy \[[@B31], [@B32]\]. On the other hand, the decidual T cell compartment at parturition has recently been shown to closely reflect that of peripheral blood, suggesting that for some components of the immune system the maternal peripheral blood is reasonable to study \[[@B33]\]. Furthermore, sampling maternal peripheral blood is much more feasible to perform longitudinally as compared to more invasive means and may still lend insight into the maternal adaptation to pregnancy.

5. Conclusions {#sec5}
==============

Successful pregnancy has previously been described as predominantly a type 2 immune response-biased phenomenon \[[@B34]--[@B36]\]. In light of the collective evidence, it seems that the description of pregnancy in terms of type 2 immune responses may be oversimplified, both in the overall description of key cytokines/growth factors as well as in the temporal dynamics, and it is in need of further refinement.
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Supplemental material accompanying this article incluldes detailed results of the number of samples with analyte concentrations below or above detection limits, interclass correlation coefficients for each cytokine, nonparametric empiric growth trajectories of individual cytokines with plots separated by individual patients, and the superimposed growth curves of MDC and IL-1b.
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![Principal components analysis of individual samples grouped by "pregnant" (+) versus "nonpregnant" (•). In (a, left), all samples are plotted with no clear separation of the groups. When only the baseline first trimester samples are plotted against the nonpregnant controls (b, right), a separation between the groups becomes apparent.](JIR2015-952571.001){#fig1}

![Unsupervised hierarchical clustering of all data. Protein levels of peripheral blood cytokines and growth factors as determined by multiplex cytokine array were log-normalized and clustered. Each row represents an individual serum sample, and each analyte measured with the multiplex cytokine array is represented by a column. Even with log-transformation, all subjects\' samples exhibited a strong tendency to cluster with other samples from the same subject, giving the impression of distinct subject-specific "bands" (labeled A--P) within the cluster.](JIR2015-952571.002){#fig2}

![Nonparametric empirical growth trajectory of IL-15 using splines.](JIR2015-952571.003){#fig3}

![Growth curve of IL-15, with data from all patients superimposed, and with the average of all of the plots represented by the dashed red line.](JIR2015-952571.004){#fig4}

![Cytokines with linear relationships to time-dependent variables.](JIR2015-952571.005){#fig5}

###### 

Comparison of protein concentrations (pg/mL) of growth factors and cytokines between controls and baseline pregnancy samples.

                                             Healthy control (*N* = 11)   Pregnancy baseline (*N* = 16)                                     
  ------------------------------------------ ---------------------------- ------------------------------- ------- --------- ------- ------- ---------
  Higher in pregnancy                                                                                                                        
   GRO*α*                                    341.6                        243.3                           742.6   1018.6    424.4   3208    \<0.001
   PDGF-AA                                   563.8                        340.9                           923.7   10740.6   2181    \>ULD   \<0.001
   TGF*α*                                    1.8                          \<LLD                           33.3    11.7      2.7     78.4    0.002
   EGF                                       24.8                         8.6                             178.2   489.4     14.6    1506    0.003
   PDGF-AB/BB                                3410.4                       493                             7482    10760.7   3650    \>ULD   0.005
  Higher in controls                                                                                                                         
   Eotaxin                                   330.9                        166.3                           651     36.8      9.8     136.9   \<0.001
   sCD40L                                    424.7                        132.7                           1423    29.2      0       1583    0.004
   IP-10                                     400.2                        198.6                           1271    162.7     57.8    380.7   0.009
   IL-17                                     14.8                         2.2                             161.6   5.5       \<LLD   46.9    0.03
   IL-6                                      7.9                          \<LLD                           82      \<LLD     \<LLD   34.3    0.03
   IL-13                                     21.3                         \<LLD                           95      \<LLD     \<LLD   37.3    0.05
   MCP-1                                     492.6                        176.9                           1043    335.2     80.5    1002    0.05
  Nonstatistically significant differences                                                                                                   
   IL1-ra                                    81.4                         \<LLD                           2087    21        \<LLD   430.4   0.07
   IFN*γ*                                    62.7                         3.4                             170     11.8      1.3     221.6   0.08
   IL-12p70                                  5.7                          \<LLD                           48.6    0.6       \<LLD   18.9    0.09
   IL-2                                      5                            \<LLD                           50.8    0.1       \<LLD   45.7    0.1
   sIL2-ra                                   \<LLD                        \<LLD                           52.1    7.2       \<LLD   71.7    0.1
   VEGF                                      476.4                        5.7                             1399    189.5     \<LLD   466.1   0.1
   IL-12p40                                  48.6                         \<LLD                           155.7   2.4       \<LLD   333.8   0.2
   IL-3                                      \<LLD                        \<LLD                           5.1     \<LLD     \<LLD   1.4     0.2
   IL-4                                      \<LLD                        \<LLD                           98.3    \<LLD     \<LLD   31.1    0.2
   MCP-3                                     10.4                         \<LLD                           43.8    15.9      \<LLD   76.5    0.2
   RANTES                                    6093.6                       1590                            \>ULD   22264.8   1696    \>ULD   0.2
   IFN*α*2                                   47                           \<LLD                           378.6   22.8      5       719.3   0.3
   IL-5                                      0.3                          \<LLD                           1.1     0.6       \<LLD   1.8     0.3
   IL-9                                      \<LLD                        \<LLD                           27      \<LLD     \<LLD   9.9     0.3
   Fractalkine                               106.6                        \<LLD                           2157    96.8      \<LLD   514.6   0.4
   MIP-1*β*                                  45.1                         \<LLD                           366     50.1      27.6    196.5   0.4
   TNF*β*                                    0.2                          \<LLD                           20.5    \<LLD     \<LLD   36.6    0.4
   G-CSF                                     25.1                         7.3                             220.6   29.2      6.3     619.8   0.5
   IL-7                                      \<LLD                        \<LLD                           29      1.3       \<LLD   219.3   0.5
   IL-8                                      12.8                         4.8                             45.2    10.8      1.4     22.8    0.5
   FGF-2                                     28.8                         11.8                            103.5   24.7      5.9     75.1    0.6
   GM-CSF                                    94.1                         14.3                            456.3   65.7      23.7    3337    0.6
   Il-1*β*                                   \<LLD                        \<LLD                           25.2    \<LLD     \<LLD   7.1     0.6
   FLT3-ligand                               7                            \<LLD                           84.1    \<LLD     \<LLD   72.8    0.7
   IL-15                                     \<LLD                        \<LLD                           11.1    0.9       \<LLD   12.1    0.8
   IL-10                                     \<LLD                        \<LLD                           19.1    \<LLD     \<LLD   17.1    0.9
   IL-1ra2                                   3                            \<LLD                           34.4    \<LLD     \<LLD   48.2    0.9
   MDC/CCL22                                 1460.4                       676                             4049    1440.8    239.1   3665    0.9
   MIP-1*α*                                  58.9                         11.6                            129     51.1      15.3    289     0.9
   TNF*α*                                    3.8                          \<LLD                           35.9    6.4       0.4     97.7    0.9

EGF = epidermal growth factor, FGF-2 = fibroblast growth factor-2, G-CSF = granulocyte colony stimulating factor, GM-CSF = granulocyte macrophage colony stimulating factor, GRO-a = growth-related oncogene alpha, IFN = interferon, IL = interleukin, IL-1ra = IL-1 receptor antagonist, IP-10 = interferon-gamma induced protein 10, MCP = monocyte chemotactic protein, MDC = macrophage-derived chemokine, MIP = macrophage inflammatory protein, PDGF = platelet-derived growth factor, RANTES = regulated on activation, normal T cell expressed and secreted, sCD40L = soluble CD40 ligand, sIL2-ra = soluble IL-2 receptor alpha, TGF-a = transforming growth factor alpha, TNF = tumor necrosis factor, and VEGF = vascular endothelial growth factor.

###### 

Cytokines with gestational week (GW) as the time covariate, ordered by decreasing within-subject variance explained by adding GW to the unconditional growth model (UGM).

  Analyte       Estimated random slope variance   Estimated scatter variance around individual\'s own trajectory   Within-subject variance explained by adding GW to UGM   Estimated fixed effect from GW   *P*
  ------------- --------------------------------- ---------------------------------------------------------------- ------------------------------------------------------- -------------------------------- ---------------
  IL-15         0.000178                          0.07753                                                          0.39                                                    0.01338                          0.0004
  IL-1*β*       0.000209                          0.08174                                                          0.38                                                    0.01543                          0.0001
  MDC/CCL22     0.000001632                       0.000937                                                         0.34                                                    −0.00163                         *P* \< 0.0001
  IL-12p70      0.000159                          0.11                                                             0.34                                                    0.00888                          0.0174
  FLT3-ligand   0.000518                          0.243                                                            0.32                                                    0.01735                          0.007
  IP-10         0.000012                          0.01545                                                          0.31                                                    0.00596                          *P* \< 0.0001
  IL-13         0.000144                          0.07619                                                          0.31                                                    0.008165                         0.0176
  IL-6          0.000325                          0.1921                                                           0.26                                                    0.01603                          0.0022
  IL-8          0.00003                           0.02932                                                          0.11                                                    0.00527                          0.0023

###### 

Cytokines with linear trimester as the time covariate, ordered by decreasing within-subject variance explained by adding trimester to the unconditional growth model (UGM).

  Analyte    Estimated random slope variance   Estimated scatter variance around individual\'s own trajectory   Within-subject variance explained by adding trimester to UGM   Estimated fixed effect from trimester   *P*
  ---------- --------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------- --------
  IL-1ra     0.04697                           0.2513                                                           0.27                                                           0.1872                                  0.0054
  IL-9       0.02779                           0.1134                                                           0.25                                                           0.1618                                  0.0011
  IL-12p40   0.08139                           0.1892                                                           0.24                                                           0.1592                                  0.0446
  sCD40L     0.09832                           0.2156                                                           0.14                                                           0.2178                                  0.0122
  IFN*α*2    0.002279                          0.01625                                                          0.20                                                           0.05875                                 0.0002
  IL-3       0.006149                          0.06967                                                          0.10                                                           0.06972                                 0.0146

###### 

Cytokines with categorical trimester as the time covariate.

  Analyte      Trim.   Estimate   Std. error   DF   *t* value   Pr \> \|*t*\|
  ------------ ------- ---------- ------------ ---- ----------- ---------------
  G-CSF                                                          
   Intercept           0.5324     0.0427       15   12.47       \<0.0001
   Trim.       1       −0.1757    0.03662      30   −4.8        \<0.0001
   Trim.       2       −0.0267    0.02718      30   −0.98       0.3334
   Trim.       3       0          .            .    .           .
  IFN*γ*                                                         
   Intercept           0.4027     0.02978      15   13.52       \<0.0001
   Trim.       1       −0.0837    0.03167      30   −2.64       0.013
   Trim.       2       −0.0367    0.02397      30   −1.53       0.1361
   Trim.       3       0          .            .    .           .
  IL-4                                                           
   Intercept           0.5254     0.05158      15   10.19       \<0.0001
   Trim.       1       −0.1826    0.08129      30   −2.25       0.0322
   Trim.       2       −0.2063    0.08505      30   −2.43       0.0215
   Trim.       3       0          .            .    .           .
  MIP-1*α*                                                       
   Intercept           0.334      0.01941      15   17.21       \<0.0001
   Trim.       1       −0.0369    0.01379      30   −2.67       0.012
   Trim.       2       −0.018     0.01025      30   −1.75       0.0898
   Trim.       3       0          .            .    .           .
  sIL2Ra                                                         
   Intercept           0.8667     0.2036       15   4.26        0.0007
   Trim.       1       −0.3954    0.186        30   −2.13       0.0418
   Trim.       2       −0.184     0.1386       30   −1.33       0.1945
   Trim.       3       0          .            .    .           .
  TGF*α*                                                         
   Intercept           0.3781     0.04092      15   9.24        \<0.0001
   Trim.       1       −0.0498    0.02372      30   −2.1        0.0442
   Trim.       2       −0.0155    0.01805      30   −0.86       0.3977
   Trim.       3       0          .            .    .           .
  TNF*β*                                                         
   Intercept           0.4825     0.09447      15   5.11        0.0001
   Trim.       1       −0.1327    0.04807      30   −2.76       0.0097
   Trim.       2       −0.0461    0.03632      30   −1.27       0.2147
   Trim.       3       0          .            .    .           .

[^1]: Academic Editor: Jacek Tabarkiewicz
